The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients

Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperphosphatemia Metabolic Diseases Nutritional and Metabolic Diseases Phosphorus Metabolism Disorders

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Shiraz University Hemodialysis Center

Shiraz, Fars, o98-711, Iran

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

hemodialysis with duration>3 months serum P level >5.5 mg/dl serum Ca>8 mg/dl.

Exclusion criteria

Mg level >3 mg/dl

Treatment and study plan

Mg Oxide

Drug

250 mg orally for 4 weeks

Other names: (Mg®, 21st Century®)

Primary outcomes

plasma phosphate level

Time frame: 4 week

Sponsors and collaborators

Lead sponsor

Shiraz University of Medical Sciences

Other

Registry information

Important dates

Study start: 2012
Primary completion: 2012
Study completion: 2012
First posted: May 15, 2013
Registry last updated: May 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed